TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05713760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin Ointment 1%
Description: Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin Ointment 1%
Description: Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
Study: NCT06475287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450
Description: The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
Study: NCT05450445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myHealthHub
Description: myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TV-only
Description: myHealthHub device equipped with the TV-only entertainment option.
Study: NCT06547398

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive radiotherapy +/- Margin Reduction
Description: Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided radiotherapy
Description: Standard radiation treatment used in the department of radiation oncology for prostate cancer
Study: NCT05437822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 2 g of tranexamic acid in 50 mL of saline
Study: NCT04778514

Intervention type: DRUG
Group type: OTHER
Intervention: Dual Prevention Pill
Description: a single over-encapsulated DPP containing a PrEP tablet and a COC

Intervention type: DRUG
Group type: OTHER
Intervention: Dual Prevention Pill
Description: a single over-encapsulated DPP containing a PrEP tablet and a COC

Intervention type: DRUG
Group type: OTHER
Intervention: PrEP and combined oral contraceptive (COC) as two separate tablets
Description: PrEP tablet and a COC as two separate tablets

Intervention type: DRUG
Group type: OTHER
Intervention: PrEP and combined oral contraceptive (COC) as two separate tablets
Description: PrEP tablet and a COC as two separate tablets
Study: NCT05635136

Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy
Description: Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
Study: NCT06429332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reversal of Oral anticoagulation within 30 minutes
Description: In situations of either an elevated INR with the use of warfarin - treatment with either 3- or 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) within 30 minutes of hospital arrival to reach and maintain an INR target \<1.3; or where there has been recent use (\<48 hours) of a direct oral anticoagulant (DOAC), use of an appropriate reversal agent within 30 minutes, where available, and according to local approvals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early intensive blood pressure lowering
Description: A systolic blood pressure (BP) target of 130-140 mmHg within 30 minutes of commencing treatment is strived for, and to maintain this BP level for the first 7 days (for patients presenting with blood pressure \<200 mmHg). If blood pressure ≥200 and \<220, a target BP of 160 mmHg should be targeted at 30 minutes, and 130-140 mmHg should be achieved in 60 minutes. If BP ≥220, target BP of 160 mmHg and should be achieved in 60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of pyrexia
Description: To achieve a body temperature target \<37.5 °C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemia treatment
Description: To maintain a blood glucose level 7-10 mmol/L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do-not-resuscitate (DNR) or withdrawal of care
Description: Refrain from the use of DNR or withdrawal of care orders for 48 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Intensive Care
Description: Immediate (\<30 min) referral to intensive care if airway, breathing and/or circulation are compromized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Neurosurgery
Description: Immediate (\<30 min) referral to neurosurgery if any of the following criteria are fulfilled:~* Large and/or rapidly evolving supratentorial ICH (\>20 ml volume)~* Any intraventricular extension~* Posterior fossa bleed, irrespective of volume~* Suspicion of a vascular malformation, independent of volume or location~* Reduction in reaction to sensory stimulation or drowsiness

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Repeat brain imaging
Description: Repeat 6-12-hour brain imaging with the physicians choice of modality, preferably computed tomography (CT), if clinical deterioration or the patient received OAC reversal treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
Study: NCT05943314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1/+CD33 CAR-T
Description: CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
Study: NCT06312293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
Study: NCT05701072

Intervention type: PROCEDURE
Intervention: Oocyte Pick Up
Description: The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.

Intervention type: PROCEDURE
Intervention: Embryo Transfer
Description: When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
Study: NCT04724902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic bandage compression
Description: The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Elastic bandage compression
Description: The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
Study: NCT06312293

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
Study: NCT06333275

Intervention type: BIOLOGICAL
Intervention: Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles
Description: First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative
Study: NCT06620146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical bathing
Description: Providing mechanical bathing (MB) is a commonly used strategy to maintain cleanness and comfort in patients with terminally illness. The electric medical bathtub (ARJO, Rhapsody) provides functions such as showering, bathing, and water massage. The MB will be operated by 2-3 nursing staff, trained hospice volunteers, or researchers. Each patient\&amp;#39;s MB process lasts about 20 minutes, including washing the hair and body with a handheld showerhead, followed by soaking in warm water for about 5-10 minutes. Based on the patient preference, the water temperature is adjusted between 38 to 40 degrees Celsius.
Study: NCT06620224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: we only use single group in this study, before the acupuncture treatment, let the participant wear the virtual reality to realize the course of the acupuncture treatment
Study: NCT05002998

Intervention type: DRUG
Group type: OTHER
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration

Intervention type: DRUG
Group type: OTHER
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration

Intervention type: DRUG
Group type: OTHER
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
Study: NCT06537076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR1005
Description: AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for AR1005 to be administered BID for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3 mg
Description: 3mg Rivastigmine will be administered BID for both active and placebo groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine 3 mg
Description: 3mg Rivastigmine will be administered BID for both active and placebo groups
Study: NCT04907643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study: NCT05201534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions in Mathematics and Cognitive Skills - Experimental
Description: After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventions in Mathematics and Cognitive Skills - Active Comparator
Description: After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program.
Study: NCT06090409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementing free/subsidized agricultural produce to encourage a plant-based diet.
Description: Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementing free/subsidized agricultural produce to encourage a plant-based diet.
Description: Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
Study: NCT05172973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN X4 THV
Description: Implantation of the SAPIEN X4 valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN X4 THV
Description: Implantation of the SAPIEN X4 valve
Study: NCT06222060

Intervention type: OTHER
Intervention: Questionnaire about Shaken Baby Syndrome
Description: Knowledge assessment questionnaire completed in the maternity ward by both parents
Study: NCT03929601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-pvvr
Description: All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab-pvvr
Description: All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Sodium Chloride
Description: Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to \<50 kg receive 0.7 mL and \> 50 kg receive 1.0 mL.
Study: NCT05438004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory nice birth
Description: discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery